List of Excipients in Branded Drug YUVEZZI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Visus Therapeutics Inc	YUVEZZI	carbachol and brimonidine tartrate	84892-275	HYDROCHLORIC ACID	2029-01-28
Visus Therapeutics Inc	YUVEZZI	carbachol and brimonidine tartrate	84892-275	HYPROMELLOSE	2029-01-28
Visus Therapeutics Inc	YUVEZZI	carbachol and brimonidine tartrate	84892-275	SODIUM HYDROXIDE	2029-01-28
Visus Therapeutics Inc	YUVEZZI	carbachol and brimonidine tartrate	84892-275	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2029-01-28
Visus Therapeutics Inc	YUVEZZI	carbachol and brimonidine tartrate	84892-275	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	2029-01-28

YUVEZZI Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

YUVEZZI is positioned as a fixed-dose inhaled combination of budesonide, glycopyrronium, and formoterol fumarate for chronic obstructive pulmonary disease. Its commercial value depends on more than the active ingredients. The core barriers are suspension stability, dose uniformity, aerosol performance, device compatibility, and control of inhaler manufacturing. The leading excipient opportunity is a high-performance metered-dose inhaler system using a hydrofluoroalkane propellant, phospholipid-based suspension aid, and controlled particle engineering.

What is YUVEZZI and which excipients are commercially relevant?

YUVEZZI is associated with the inhaled triple therapy combination used in other markets under brands including Breztri Aerosphere and Trixeo Aerosphere. Public product information for comparable budesonide/glycopyrronium/formoterol pressurized metered-dose inhalers identifies a formulation built around:

Component	Function
Budesonide	Inhaled corticosteroid
Glycopyrronium bromide	Long-acting muscarinic antagonist
Formoterol fumarate	Long-acting beta-2 agonist
HFA-134a	Propellant
Phospholipid, commonly DSPC	Suspension aid and aerosol-performance excipient
Calcium chloride or related particle-engineering component	Supports porous carrier particle formation
Aluminum canister, metering valve and actuator	Dose delivery system

The precise YUVEZZI formulation should be distinguished from the formulation of comparable products. Brand names can refer to different regional products, development stages, or regulatory presentations.

The principal formulation problem is maintaining three chemically and physically different micronized drug substances in a uniform suspension throughout the product shelf life. Budesonide is a corticosteroid with low aqueous solubility. Glycopyrronium bromide is an ionic salt. Formoterol fumarate is present at a low dose relative to the other actives. These differences create risks in particle segregation, sedimentation, valve retention, agglomeration, and emitted-dose variability.

How does the YUVEZZI excipient system work?

Aerosphere-type triple inhalers use a pressurized suspension approach rather than a simple solution formulation. The active particles are suspended in liquefied propellant. A phospholipid-based porous particle system improves suspension behavior and aerosolization.

Propellant strategy

HFA-134a remains a widely used propellant for pressurized metered-dose inhalers. It has established regulatory precedent, broad supply availability, and compatibility with many commercial valve systems. Its limitations include greenhouse-gas impact and long-term pressure and packaging requirements.

The principal commercial opportunity is the transition to lower-global-warming-potential propellants, especially HFA-152a and hydrofluoroolefin-based systems. A reformulated YUVEZZI-type product would require new development work covering:

• valve and canister compatibility;
• vapor pressure and fill weight;
• suspension stability;
• extractables and leachables;
• delivered-dose uniformity;
• plume geometry;
• aerodynamic particle-size distribution;
• flammability and facility controls for HFA-152a;
• comparative clinical or bridging requirements.

Propellant substitution is therefore a potential lifecycle-management opportunity, but it is not a simple excipient replacement.

Phospholipid suspension aid

1,2-Distearoyl-sn-glycero-3-phosphocholine, commonly known as DSPC, is a high-value excipient candidate for inhaled suspension products. It can form porous particles that reduce direct contact between micronized drug particles and improve aerosol dispersion.

Commercial advantages include:

• improved physical stability;
• reduced aggregation;
• enhanced emitted fraction;
• lower dependence on traditional surfactant systems;
• potential compatibility with multiple active ingredients.

DSPC supply is more specialized than standard oral excipients. Suppliers must demonstrate high purity, low bioburden, control of residual solvents, consistent fatty-acid composition, and suitable particle-engineering performance.

A supplier that can offer GMP-grade DSPC with documented inhalation toxicology and reliable global supply would have a stronger commercial position than a commodity phospholipid supplier.

Calcium chloride and porous-particle technology

Calcium chloride may be used during manufacture of porous phospholipid particles or related excipient structures. Its value is process-dependent. The material itself is inexpensive, but the manufacturing know-how that controls porosity, moisture, particle strength, and residual inorganic content can be difficult to replicate.

The higher-margin opportunity is therefore not calcium chloride supply alone. It is the provision of:

• engineered porous particles;
• spray-drying services;
• particle-size control;
• moisture management;
• analytical characterization;
• formulation-development support;
• scale-up under GMP conditions.

This creates a potential contract development and manufacturing opportunity for specialist inhalation companies.

What formulation patents are likely to protect YUVEZZI?

The strongest intellectual-property positions in a product of this type usually cover the formulation architecture and manufacturing process rather than the basic existence of the three active ingredients.

Relevant claim categories include:

Patent area	Typical protected subject matter
Pharmaceutical composition	Specific ratios of budesonide, glycopyrronium and formoterol
Suspension system	Co-suspension of multiple micronized actives in HFA propellant
Porous particles	Phospholipid-based carrier particles with defined morphology
Particle engineering	Spray-drying or controlled precipitation processes
Device integration	Canister, valve, actuator and dose-counter configuration
Dose delivery	Delivered-dose uniformity and aerodynamic performance
Manufacturing	Mixing, filling and suspension-homogenization processes
Method of use	COPD maintenance treatment and exacerbation reduction
Stability	Formulations meeting defined shelf-life and performance criteria

The active-ingredient patents for budesonide, glycopyrronium and formoterol are generally older than the combination-product rights. Commercial protection is more likely to depend on formulation, device, process and method-of-use claims.

A freedom-to-operate review should separate four patent layers:

1. Active pharmaceutical ingredients.
2. Triple-combination composition.
3. Co-suspension and porous-particle platform.
4. Inhaler device and manufacturing process.

A competitor may avoid a narrow composition claim while still infringing a platform or device claim.

What is the Orange Book status of YUVEZZI?

YUVEZZI does not appear to be the primary U.S. brand name for the budesonide/glycopyrronium/formoterol product. In the United States, the corresponding product is marketed as Breztri Aerosphere. Orange Book analysis should therefore be conducted against the U.S. approved product and its sponsor, not against the YUVEZZI name.

For a U.S. generic entrant, the relevant regulatory route would generally be an abbreviated new drug application with Paragraph IV certification against applicable listed patents. The principal challenges would involve:

• proving pharmaceutical equivalence;
• demonstrating equivalent delivered dose;
• matching aerodynamic particle-size distribution;
• showing equivalent device performance;
• addressing formulation and manufacturing patents;
• resolving any patent litigation before commercial launch.

The Orange Book does not capture every potentially relevant patent. Device, process and manufacturing rights may appear elsewhere, including patent assignment databases, litigation records and regulatory submissions.

When does YUVEZZI lose exclusivity?

Exclusivity depends on the jurisdiction, approval date, patent filings, patent-term adjustments, pediatric extensions and regulatory exclusivity. A reliable expiration date cannot be inferred from the brand name alone.

For a comparable U.S. product, the exclusivity stack may include:

Protection type	Relevance
New chemical entity exclusivity	Usually limited because the actives are established
New combination exclusivity	May apply depending on approval history
New clinical investigation exclusivity	May cover a new indication or formulation
Patent term	Often the principal commercial barrier
Pediatric extension	Can add six months to eligible protections
Orphan exclusivity	Generally indication-specific and not assumed for COPD
Device-related patents	May delay an equivalent generic device

Generic entry could occur after the final enforceable patent expires, after successful patent litigation, or under a settlement agreement permitting an earlier date. The practical date can differ by market because patent families have different national filings and term adjustments.

What generic entry risks exist for YUVEZZI?

YUVEZZI-type products have higher generic-development complexity than conventional oral tablets. The most important risk is that a generic can meet chemical sameness requirements while failing to reproduce the reference product's aerosol behavior.

Key technical barriers include:

• three active ingredients with different densities and particle sizes;
• low-dose formoterol distribution;
• suspension settling;
• valve and actuator retention;
• moisture ingress;
• canister-coating interactions;
• dose uniformity at beginning, middle and end of life;
• equivalence across priming and repriming conditions;
• device resistance and plume geometry.

A generic company may pursue one of three strategies:

1. A direct equivalent using the reference device or a closely similar device.
2. A device-substitution strategy supported by comparative in vitro and clinical data.
3. A 505(b)(2)-type reformulation using a different propellant, excipient system or delivery device.

The first strategy has the lowest clinical risk but the highest dependence on patent and device access. The third may create stronger differentiation but carries greater development and regulatory risk.

Which companies could challenge the YUVEZZI market?

The competitive field includes large inhalation companies with established device and respiratory-development capabilities:

Company type	Likely competitive advantage
AstraZeneca	Originator respiratory portfolio and inhaler platform
GlaxoSmithKline	Trelegy Ellipta and respiratory commercialization
Boehringer Ingelheim	Spiriva, Stiolto and device expertise
Viatris and Kindeva	Generic and contract inhalation manufacturing
Cipla	Respiratory generics and inhaler commercialization
Lupin	Complex inhalation product development
Teva	Generic respiratory portfolio
Recipharm and Catalent	Inhalation manufacturing and development services

The most credible challengers are companies that already operate metered-dose inhaler filling lines, possess device-engineering capabilities, and have regulatory experience with complex inhaled products.

What commercial opportunities exist in YUVEZZI excipients?

GMP-grade phospholipids

The strongest specialty-excipient opportunity is inhalation-grade DSPC or an equivalent phospholipid system. Pricing power depends on:

• regulatory qualification;
• batch-to-batch purity;
• validated supply chain;
• low endotoxin and bioburden profile;
• technical support;
• ability to scale with global demand.

A supplier with only pharmaceutical-grade material but no inhalation-specific documentation may face qualification delays.

Engineered porous particles

Porous particle manufacturing has a higher strategic value than raw-material supply. Suppliers can offer proprietary particle morphology, spray-drying capacity, and analytical packages. This model creates switching costs because a customer may need to repeat extensive formulation and device testing after changing supplier or particle specifications.

Low-GWP propellant conversion

The shift to lower-emission propellants creates opportunities for propellant manufacturers, valve suppliers, canister producers and contract developers. A YUVEZZI-type product is technically attractive for reformulation because its current delivery architecture is already based on a pressurized inhaler.

The commercial constraint is capacity. Propellant conversion across multiple inhaled products may create temporary supply shortages and increase qualification lead times.

Inhaler components

Canisters, metering valves, actuators and dose counters are strategic components. Opportunities exist for suppliers that can demonstrate:

• low extractables and leachables;
• consistent metering volume;
• compatibility with new propellants;
• improved dose counters;
• reduced residual drug retention;
• lower manufacturing scrap.

Contract manufacturing

Complex triple inhalers require specialized filling and analytical capabilities. Contract manufacturers can monetize:

• formulation screening;
• spray-dried particle production;
• suspension preparation;
• cold filling or pressure filling;
• device assembly;
• stability testing;
• aerodynamic performance testing;
• regulatory-support documentation.

How strong is the YUVEZZI patent estate?

The estate is potentially strong when claims cover the interaction among formulation, particle engineering and device delivery. It is weaker if protection is limited to broad combination claims that are vulnerable to invalidity challenges or design-around approaches.

Patent strength should be assessed using five measures:

Measure	High-strength indicator
Claim breadth	Covers composition, particles and delivery system
Remaining term	Long enforceable life after market approval
Family depth	Continuation and divisional applications
Geographic coverage	U.S., Europe, China, Japan and major commercial markets
Design-around difficulty	Requires a different clinical or device platform

The most defensible rights generally claim measurable performance parameters, such as emitted dose, fine-particle fraction, particle morphology and stability, when those parameters are tied to a defined formulation and manufacturing process.

What litigation and settlement risks affect generic launch?

A Paragraph IV challenge would likely produce litigation over combination, formulation, device or process patents. Settlement agreements could permit entry before patent expiry, subject to conditions involving launch dates, authorized-generic rights, supply arrangements or geographic limits.

For investors and licensees, the important diligence points are:

• whether patents are listed in the relevant Orange Book;
• whether the sponsor has filed infringement complaints;
• whether any preliminary injunction was granted;
• whether a settlement contains a launch license;
• whether authorized-generic provisions change expected price erosion;
• whether European or Chinese litigation proceeds independently.

Patent litigation may not eliminate commercial risk. A generic can lose a case yet enter after settlement, while a successful invalidity decision may be followed by manufacturing or regulatory delays.

How does YUVEZZI compare with other COPD triple therapies?

Product type	Delivery platform	Excipient opportunity	Generic difficulty
YUVEZZI/Breztri-type product	Pressurized metered-dose inhaler	DSPC, engineered particles, propellant	High
Trelegy-type product	Dry-powder inhaler	Lactose or carrier-particle system	High, but different technical risks
Conventional dual inhaler	pMDI or DPI	Simpler suspension or carrier system	Moderate
Nebulized triple therapy	Nebulizer solution or suspension	Solubilizers, buffers, tonicity agents	Variable

YUVEZZI-type pMDIs offer a differentiated opportunity for patients who have difficulty generating sufficient inspiratory flow for a dry-powder inhaler. The tradeoff is greater dependence on device coordination and specialized manufacturing.

Key Takeaways

• YUVEZZI's commercial formulation opportunity centers on inhalation-grade phospholipids, porous particles, propellants and device components.
• DSPC-type materials are more strategically valuable than commodity salts because they influence suspension stability and aerosol performance.
• The principal generic barrier is proving equivalent delivery performance for three chemically different active ingredients.
• Lower-global-warming-potential propellants create a lifecycle-management opportunity but require extensive device and stability work.
• Patent protection is likely to be concentrated in formulation, particle engineering, device and manufacturing claims.
• U.S. Orange Book and Paragraph IV analysis should be performed under the corresponding U.S. product listing, rather than relying on the YUVEZZI brand name.
• The strongest commercial opportunities are engineered excipients, inhaler components, propellant conversion and specialized contract manufacturing.

FAQs

Is DSPC a suitable excipient for YUVEZZI-type inhalers?

Yes. DSPC is suitable for phospholipid-based suspension and porous-particle systems used in pressurized inhalers, subject to inhalation-grade quality, impurity controls and product-specific regulatory qualification.

Can a generic use a different propellant from the reference YUVEZZI product?

Potentially, but a different propellant would require evidence addressing aerosol performance, dose delivery, stability, device compatibility, extractables and leachables, and applicable regulatory equivalence standards.

Are lactose carriers relevant to YUVEZZI?

Lactose is more commonly associated with dry-powder inhalers. It is not the principal excipient strategy for a pressurized metered-dose YUVEZZI-type product.

What is the highest-value licensing opportunity?

The strongest licensing targets are proprietary porous-particle technology, inhalation-grade phospholipid supply, lower-emission propellant conversion and complex pMDI manufacturing capacity.

Can formulation patents block a device-substitution generic?

Yes. A device-substitution product may still infringe composition, suspension, particle-engineering or manufacturing patents even if it uses a different actuator or canister.

References

1. AstraZeneca. (2024). Annual report and Form 20-F. AstraZeneca PLC.

2. U.S. Food and Drug Administration. (2024). Breztri Aerosphere prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.

5. International Council for Harmonisation. (2005). Q6A: Specifications for new drug substances and products. ICH.

6. U.S. Pharmacopeia. (2024). General chapter <601>: Inhalation and nasal drug products. United States Pharmacopeial Convention.